RNA-seq analysis was performed to study transcriptional changes in these cells. Results: We found that bryostatin-1 improved the expansion and decreased PD-1 expression of HIV-specific CD8+ T cells.

A new research paper was published in Oncotarget's Volume 16 on January 20, 2025, titled "Anti-correlation of KLRG1 and PD-1 expression in human tumor CD8 T cells." The study authored by Dr. Steven A.

Cancer remains the second leading cause of death in the US, accounting for 25% of all deaths nationwide. Immunotherapy techniques bolster the immune cells’ ability to target malignant cancer cells and ...

编辑丨王多鱼排版丨水成文抗 PD-1 联合仑伐替尼（lenvatinib，一种多靶点受体酪氨酸激酶抑制剂）治疗在多种肿瘤中均显示出临床疗效，但潜在的免疫学机制尚不清楚。2025 年 1 月 30 ...

引言肿瘤免疫治疗已是癌症治疗的重要方向，尤其是免疫检查点抑制剂（如PD-1/PD-L1抑制剂）的成功应用，使得癌症治疗迎来了新的曙光。然而，即使这些治疗方法在部分患者中表现出显著疗效，仍有大量患者未能得到有效的治疗。这种现象背后，隐藏着肿瘤免疫逃逸和 ...

Syndecan-4 (SDC4) is a receptor protein of CD8 + T cells. FTO inhibited the activation and recruitment of tumour-infiltrating ... Targeting FTO may suppress tumour growth and enhance the therapeutic ...

Objective Patients with increased PD-L1 + host cells in tumours are more potent to benefit from antiprogrammed death-1/programmed death ligand-1 (PD-L1) treatment, but the underlying mechanism is ...

Priya Hays, Hays Documentation Specialists, discusses innovations and advancements in the development of personalized cancer ...

TIGIT靶点，曾被誉为“下一个PD-1”，在免疫治疗领域备受瞩目。然而，其研发之路却充满坎坷，众多药企纷纷折戟。近期，阿斯利康的PD-1/TIGIT双抗药物Rilvegostomig启动了头对头帕博利珠单抗（K药）的III期研究，为TIGIT靶点带 ...